ESSA Pharma Inc.
EPIXDelisted Oct 9, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001633932
ESSA Pharma Inc. was delisted on Oct 9, 2025; its insiders filed their last Form 4 on Oct 15, 2025; 32 institutions reported holding it in 13F filings for Q3 2025, worth $4.30M in total; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 32
- Q3 2025, −4 vs. previous quarter
- 13F value
- $4.30M
- Reported value at the end of Q3 2025
- Superinvestors holding
- 0
- At the end of Q3 2025
Superinvestors holding EPIX, Q3 2025
No superinvestor reported holding EPIX at the end of Q3 2025.
Latest insider trades
Open-market purchases and sales by ESSA Pharma Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 7, 2025 (view filing)4:36 PM ET | Aug 5 | 2 days | Biotechnology Value Fund L P and 9 others10% Owner | SSale | −156 | $1.88 | −$292.95 | 0.0%560.8K after | 3 lots |
| Nov 5, 2024 (view filing)12:06 PM ET | Nov 1 | 4 days | BB Biotech AG and 1 other10% Owner | SSale | −7.88M | $1.53 | −$12.0M | −100.0%0 after | 4 lots |
| Oct 7, 2024 (view filing) | Oct 7 | Same day | Virsik PeterChief Operating Officer | SSale | −694 | $6.03 | −$4.18K | −8.2%7.78K after | 10b5-1 |
| Sep 9, 2024 (view filing) | Sep 9 | Same day | Virsik PeterChief Operating Officer | SSale | −694 | $6.00 | −$4.16K | −7.6%8.47K after | 10b5-1 |
| Sep 3, 2024 (view filing) | Sep 3 | Same day | Virsik PeterChief Operating Officer | SSale | −2.08K | $6.03 | −$12.6K | −18.5%9.16K after | 10b5-1 |
| May 6, 2024 (view filing) | May 6 | Same day | Virsik PeterChief Operating Officer | SSale | −694 | $6.95 | −$4.82K | −5.8%11.2K after | 10b5-1 |
| Apr 5, 2024 (view filing) | Apr 5 | Same day | Virsik PeterChief Operating Officer | SSale | −694 | $7.94 | −$5.51K | −5.5%11.9K after | 10b5-1 |
| Mar 5, 2024 (view filing) | Mar 5 | Same day | Virsik PeterChief Operating Officer | SSale | −694 | $8.98 | −$6.23K | −5.2%12.6K after | 10b5-1 |
| Feb 7, 2024 (view filing) | Feb 6 | 1 day | Virsik PeterChief Operating Officer | SSale | −72.8K | $10.29 | −$748.9K | −84.5%13.3K after | 10b5-1 |
| Feb 6, 2024 (view filing) | Feb 5 | 1 day | Virsik PeterChief Operating Officer | SSale | −1.19K | $9.58 | −$11.4K | −8.2%13.3K after | 2 lots10b5-1 |
Top 10 13F holders, Q3 2025
The largest institutional positions in ESSA Pharma Inc. at the end of Q3 2025; share changes are against Q2 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BVF Inc | 11,668,473 | $2.23M | 0.09% | +2,919,844+33.4% | Added |
| Soleus Capital Management, L.P. | 4,362,026 | $833.1K | 0.04% | +2,100,000+92.8% | Added |
| Morgan Stanley | 1,904,061 | $363.7K | 0.00% | −2,305,609−54.8% | Reduced |
| Pfizer Inc | 1,675,000 | $319.9K | 0.07% | 00.0% | Unchanged |
| Bank of America Corp | 591,834 | $113.0K | 0.00% | −36,096−5.7% | Reduced |
| LMR Partners LLP | 540,984 | $103.3K | 0.00% | +340,984+170.5% | Added |
| Shay Capital LLC | 536,533 | $102.5K | 0.02% | +512,185+2,103.6% | Added |
| Two Sigma Investments, LP | 336,164 | $64.2K | 0.00% | +113,837+51.2% | Added |
| Two Sigma Advisers, LP | 214,800 | $41.0K | 0.00% | −46,000−17.6% | Reduced |
| Citadel Advisors LLC | 144,449 | $27.6K | 0.00% | +90,410+167.3% | Added |
Holders of 5% or more of EPIX
Holders whose latest Schedule 13D or 13G filing reports 5% or more of ESSA Pharma Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Soleus Capital Master Fund, L.P. | 13D/A | 9.80%4.36M shares | +4.70 ppfrom 5.10% | Apr 15, 20253 filings | Jul 21, 2025 | SEC |
| BML Investment Partners, L.P. | 13D | 9.50%4.22M shares | 0.00 ppfrom 9.50% | Feb 14, 20253 filings | Apr 24, 2025 | SEC |
| Soleus Capital, LLC | 13G/A | 5.10%2.26M shares | – | Feb 12, 20215 filings | Feb 11, 2025 | SEC |